Format

Send to

Choose Destination
See comment in PubMed Commons below
IDrugs. 2010 Mar;13(3):139-41.

28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics.

Author information

1
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. sophie.gale@thomsonreuters.com

Abstract

The JPMorgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing their achievements in 2009 and expectations for 2010. This conference report highlights presentations from Exelixis Inc and Nektar Therapeutics. Investigational drugs from Exelixis, including XL-184 (in collaboration with Bristol-Myers Squibb Co), XL-147 and XL-765 (both in collaboration with sanofi-aventis), and from Nektar, including NKTR-118 and NKTR-119 (both now licensed to AstraZeneca plc), NKTR-171, NKTR-181, NKTR-194, NKTR-102, and NKTR-105, are discussed.

PMID:
20191424
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center